Comparison of survival in nonresected well differentiated and poorly differentiated adenocarcinoma of the lung

Author:

Saijo N.,Niitani H.,Tominaga K.,Eguchi K.,Koketsu H.,Fujino T.,Ishikawa S.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Reference14 articles.

1. Bergsagel DE, Jenkins RDT, Pringel JF (1972) Lung cancer: Clinical trial of radiotherapy alone vs. radiotherapy plus cyclophosphamide. Cancer 30:621?627

2. Bitran JD, Dresser RK, DeMesser T, Shapiro CM, Billings A, Rubenstein L, Evans R, Colman M, Griem M, Golomb HM (1978) Combined modality therapy for stage III non-oat cell bronchogenic carcinoma. Cancer Treat Rep 62:327?332

3. Brittell JC, Eagan RT, Ingle JN, Creagan ET, Rubin J, Frytak S (1978) cis-dichlorodiammineplatinum (II) alone follwed by adrinamycin plus cyclophosphamide at progression versus cis-dichlorodiammineplatinum (II), adriamycin, and cyclophophamide in combination for adenocarcinoma of the lung. Cancer Treat Rep 62:1207?1210

4. Issel BF, Valdivieso M, Body GP (1978) Chemotherapy for adenocarcinoma and large cell anaplastic carcinoma of the lung with futraful, adriamycin, and cis-dichlorodiammine-platinum. Cancer Treat Rep 62:1089?1091

5. Koketsu H, Subtype of adenocarcinoma classified by cytology. (Personal communication)

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3